{"created":"2023-05-15T16:41:38.210418+00:00","id":16331,"links":{},"metadata":{"_buckets":{"deposit":"dfddeb5d-8c9f-4692-8ba9-8d001c12c65e"},"_deposit":{"created_by":2,"id":"16331","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"16331"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00016331","sets":["8:9"]},"author_link":["61684","61681","61679","61682","61678","61680","61683"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-08","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"270","bibliographicPageStart":"263","bibliographicVolumeNumber":"23","bibliographic_titles":[{"bibliographic_title":"Cardiovascular Drugs and Therapy"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"PURPOSE: The authors examined whether olprinone, a phosphodiesterase type 3 inhibitor, or isoflurane, a volatile anesthetic, could protect the heart against myocardial infarction in type 2 diabetic rats and whether the underlying mechanisms involve protein kinase C (PKC), mitochondrial ATP-sensitive potassium (m-K(ATP)) channels, or the phosphatidylinositol 3-kinase (PI3K)-Akt pathway. METHODS: All rats underwent 30 min of coronary artery occlusion followed by 2 h of reperfusion. Wistar rats received isoflurane or olprinone before ischemia with or without the PKC inhibitor chelerythrine (CHE), the m-K(ATP) channel blocker 5-hydroxydecanoic acid (5HD), or the PI3K-Akt inhibitor LY294002 (LY). Goto-Kakizaki (GK) rats were randomly assigned to receive isoflurane or olprinone. In another group, GK rats received LY before the olprinone. RESULTS: In the Wistar rats, both isoflurane (38 +/- 11%) and olprinone (40 +/- 11%) reduced infarct size as compared to the control group (59 +/- 8%). In the GK rats, olprinone (41 +/- 9%) but not isoflurane (53 +/- 11%) reduced infarct size as compared to the GK control group (58 +/- 14%). The beneficial effects of olprinone were blocked by LY (58 +/- 14%). In the Wistar rats, CHE, 5HD, and LY prevented isoflurane-induced reductions of infarct size. On the other hand, LY but not CHE or 5HD prevented olprinone-induced reductions of infarct size. CONCLUSIONS: Olprinone but not isoflurane protects the heart against myocardial infarction in type 2 diabetic rats. The olprinone-induced cardioprotective effect is mediated by the PI3K-Akt pathway but not PKC or m-K(ATP) channels.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Cardiovascular Drugs and Therapy, 23(4), pp.263-270; 2009","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer"}]},"item_2_relation_11":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"19597978","subitem_relation_type_select":"PMID"}}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1007/s10557-009-6184-5","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c Springer Science+Business Media, LLC 2009"},{"subitem_rights":"The original publication is available at www.springerlink.com"}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA10691796","subitem_source_identifier_type":"NCID"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"09203206","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"1573-7241","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Matsumoto, Shuhei"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Cho, Sungsam"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tosaka, Shinya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ureshino, Hiroyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Maekawa, Takuji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hara, Tetsuya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sumikawa, Koji"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-23"}],"displaytype":"detail","filename":"CDT23_4_263.pdf","filesize":[{"value":"483.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"CDT23_4_263.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/16331/files/CDT23_4_263.pdf"},"version_id":"b494f692-00c4-4f8c-8b37-517bb8c5997c"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Olprinone","subitem_subject_scheme":"Other"},{"subitem_subject":"isoflurane","subitem_subject_scheme":"Other"},{"subitem_subject":"diabetes","subitem_subject_scheme":"Other"},{"subitem_subject":"mitochondrial ATP-sensitive potassium channels","subitem_subject_scheme":"Other"},{"subitem_subject":"phosphatidylinositol 3-kinase-Akt","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway."}]},"item_type_id":"2","owner":"2","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2009-10-02"},"publish_date":"2009-10-02","publish_status":"0","recid":"16331","relation_version_is_last":true,"title":["Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway."],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-17T20:49:28.013713+00:00"}